Latest news with #Parkinsonism
Yahoo
14-05-2025
- Business
- Yahoo
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
-- Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstrated 97% ORR and 68% CR/sCR at a median follow-up of 12.6 months -- -- No delayed neurotoxicities including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed to date with anito-cel -- -- iMMagine-1 data to be presented during an oral presentation at EHA2025 on Saturday, June 14, 2025 -- -- Company to host a live webcast event with an expert panel of clinicians during EHA2025 -- REDWOOD CITY, Calif., May 14, 2025--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan on June 14, 2025. Anito-cel is partnered with Kite, a Gilead Company. The Phase 2 iMMagine-1 data are from a May 1, 2025 data cutoff date, including all 117 patients with a median follow-up of 12.6 months and a minimum follow-up of four months after treatment with anito-cel. All patients received a single infusion of anito-cel (target dose of 115×106 CAR+ viable T cells). 101 of 117 patients (86%) were triple refractory, and 48 of 117 patients (41%) were penta refractory. Patients received a median of three prior lines of therapy, with 60 of 117 patients (51%) having received three prior lines. Overall response rate (ORR) was 97% (114/117) with a complete response/stringent complete response (CR/sCR) rate of 68% (79/117) and a very good partial response or higher (>VGPR) rate of 85% (100/117), per International Myeloma Working Group (IMWG) criteria as investigator-assessed. Of those evaluable for minimal residual disease (MRD) testing at the time of this data cut, 93.3% (70/75) achieved MRD negativity at a minimum of 10-5 sensitivity. Six-month progression-free survival (PFS) and overall survival (OS) rates were 91.9% and 96.6%, respectively, and 12-month PFS and OS rates were 78.8% and 95.2%, respectively. Median PFS and median OS have not been reached. No delayed or non-immune effector cell-associated neurotoxicity syndrome (ICANS) neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed to date with anito-cel. No additional treatment- or therapy-related deaths or Grade ≥3 cytokine release syndrome (CRS) or ICANS events have occurred since the previous data presentation in December 2024. Conclusions Preliminary results from the Phase 2 iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a fourth-line or higher (4L+) RRMM population, including triple- and penta-class refractory disease. Notably, no delayed or non-ICANS neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed with anito-cel to date. "These clinical data from our registrational study continue to support our belief that anito-cel has the potential to address the needs of myeloma patients and the physicians who serve them," said Rami Elghandour, Arcellx's Chairman and Chief Executive Officer. "There is no cure for multiple myeloma. We believe there remains an unmet medical need for CAR-T therapies that are efficacious, safe, and accessible. Anito-cel has the unique potential to address these needs thanks to our differentiated technology, our incredible and entrepreneurial team, the robust clinical data generated to date, and our strong partnership with Kite. Our 2026 commercial launch plans for anito-cel with our partners at Kite are well underway and we are excited for the opportunity to advance anito-cel in support of the myeloma community. We look forward to sharing these data with the clinical community at EHA and are honored that the iMMagine-1 data will be presented during an oral presentation on Saturday, June 14." EHA2025 Presentation Details Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the iMMagine-1 Trial Speaker: Gurbakhash Kaur, M.D., Assistant Professor of Internal Medicine, Mount Sinai Health SystemSession Title: s431 Treatment of relapsed and/or refractory multiple myeloma (RRMM)Session Date: June 14, 2025Session Time: 17:00-18:15 CESTPublication Number: S201Presentation Title: S201 Phase 2 Registrational Study of Anitocabtagene Autoleucel for Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results from iMMagine-1 About Multiple Myeloma Multiple Myeloma (MM) is a type of hematological cancer in which diseased plasma cells proliferate and accumulate in the bone marrow, crowding out healthy blood cells and causing bone lesions, loss of bone density, and bone fractures. These abnormal plasma cells also produce excessive quantities of an abnormal immunoglobulin fragment, called a myeloma protein (M protein), causing kidney damage and impairing the patient's immune function. MM is the third most common hematological malignancy in the United States and Europe, representing approximately 10% of all hematological cancer cases and 20% of deaths due to hematological malignancies. The median age of patients at diagnosis is 69 years with one-third of patients diagnosed at an age of at least 75 years. Because MM tends to afflict patients at an advanced stage of life, patients often have multiple co-morbidities and toxicities that can quickly escalate and become life-endangering. About Anitocabtagene Autoleucel (anito-cel) Anitocabtagene autoleucel (anito-cel, previously ddBCMA) is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes Arcellx's novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. This combination may allow for the effective elimination of multiple myeloma cells without severe immunotoxicity. Anito-cel has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the U.S. Food and Drug Administration. About Arcellx and Kite Collaboration Arcellx and Kite, a Gilead Company, formed a global strategic collaboration and license agreement to co-develop and co-commercialize anito-cel for patients with multiple myeloma. Anito-cel is currently being developed in a Phase 2 registrational pivotal study and a global Phase 3 randomized controlled study for relapsed and/or refractory multiple myeloma (RRMM). Kite and Arcellx will jointly commercialize the anito-cel asset in the United States, and Kite will commercialize the product outside the United States. About Arcellx, Inc. Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. For more information on Arcellx, please visit Follow Arcellx on X @arcellx and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including, but not limited to, statements regarding the safety and efficacy of anito-cel, the promising clinical profile of anito-cel, the expectation of anito-cel to be a differentiated CAR-T treatment option for RRMM, the potential of anito-cel as an outpatient therapy, and the planned commercial development of anito-cel both inside and outside the United States. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including those set forth in Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission (SEC) on May 8, 2025, and the other documents that Arcellx may file from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. View source version on Contacts Investor Contact: Myesha LacyArcellx, 510-418-2412 Media Contact: Andrea CohenSam Brown LLCandreacohen@ 917-209-7163 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
14-05-2025
- Business
- Business Wire
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan on June 14, 2025. Anito-cel is partnered with Kite, a Gilead Company. The Phase 2 iMMagine-1 data are from a May 1, 2025 data cutoff date, including all 117 patients with a median follow-up of 12.6 months and a minimum follow-up of four months after treatment with anito-cel. All patients received a single infusion of anito-cel (target dose of 115×10 6 CAR+ viable T cells). 101 of 117 patients (86%) were triple refractory, and 48 of 117 patients (41%) were penta refractory. Patients received a median of three prior lines of therapy, with 60 of 117 patients (51%) having received three prior lines. Overall response rate (ORR) was 97% (114/117) with a complete response/stringent complete response (CR/sCR) rate of 68% (79/117) and a very good partial response or higher (>VGPR) rate of 85% (100/117), per International Myeloma Working Group (IMWG) criteria as investigator-assessed. Of those evaluable for minimal residual disease (MRD) testing at the time of this data cut, 93.3% (70/75) achieved MRD negativity at a minimum of 10 -5 sensitivity. Six-month progression-free survival (PFS) and overall survival (OS) rates were 91.9% and 96.6%, respectively, and 12-month PFS and OS rates were 78.8% and 95.2%, respectively. Median PFS and median OS have not been reached. No delayed or non-immune effector cell-associated neurotoxicity syndrome (ICANS) neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed to date with anito-cel. No additional treatment- or therapy-related deaths or Grade ≥3 cytokine release syndrome (CRS) or ICANS events have occurred since the previous data presentation in December 2024. Conclusions Preliminary results from the Phase 2 iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a fourth-line or higher (4L+) RRMM population, including triple- and penta-class refractory disease. Notably, no delayed or non-ICANS neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed with anito-cel to date. 'These clinical data from our registrational study continue to support our belief that anito-cel has the potential to address the needs of myeloma patients and the physicians who serve them,' said Rami Elghandour, Arcellx's Chairman and Chief Executive Officer. 'There is no cure for multiple myeloma. We believe there remains an unmet medical need for CAR-T therapies that are efficacious, safe, and accessible. Anito-cel has the unique potential to address these needs thanks to our differentiated technology, our incredible and entrepreneurial team, the robust clinical data generated to date, and our strong partnership with Kite. Our 2026 commercial launch plans for anito-cel with our partners at Kite are well underway and we are excited for the opportunity to advance anito-cel in support of the myeloma community. We look forward to sharing these data with the clinical community at EHA and are honored that the iMMagine-1 data will be presented during an oral presentation on Saturday, June 14.' EHA2025 Presentation Details Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the iMMagine-1 Trial Speaker: Gurbakhash Kaur, M.D., Assistant Professor of Internal Medicine, Mount Sinai Health System Session Title: s431 Treatment of relapsed and/or refractory multiple myeloma (RRMM) Session Date: June 14, 2025 Session Time: 17:00-18:15 CEST Publication Number: S201 Presentation Title: S201 Phase 2 Registrational Study of Anitocabtagene Autoleucel for Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results from iMMagine-1 About Multiple Myeloma Multiple Myeloma (MM) is a type of hematological cancer in which diseased plasma cells proliferate and accumulate in the bone marrow, crowding out healthy blood cells and causing bone lesions, loss of bone density, and bone fractures. These abnormal plasma cells also produce excessive quantities of an abnormal immunoglobulin fragment, called a myeloma protein (M protein), causing kidney damage and impairing the patient's immune function. MM is the third most common hematological malignancy in the United States and Europe, representing approximately 10% of all hematological cancer cases and 20% of deaths due to hematological malignancies. The median age of patients at diagnosis is 69 years with one-third of patients diagnosed at an age of at least 75 years. Because MM tends to afflict patients at an advanced stage of life, patients often have multiple co-morbidities and toxicities that can quickly escalate and become life-endangering. About Anitocabtagene Autoleucel (anito-cel) Anitocabtagene autoleucel (anito-cel, previously ddBCMA) is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes Arcellx's novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. This combination may allow for the effective elimination of multiple myeloma cells without severe immunotoxicity. Anito-cel has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the U.S. Food and Drug Administration. About Arcellx and Kite Collaboration Arcellx and Kite, a Gilead Company, formed a global strategic collaboration and license agreement to co-develop and co-commercialize anito-cel for patients with multiple myeloma. Anito-cel is currently being developed in a Phase 2 registrational pivotal study and a global Phase 3 randomized controlled study for relapsed and/or refractory multiple myeloma (RRMM). Kite and Arcellx will jointly commercialize the anito-cel asset in the United States, and Kite will commercialize the product outside the United States. About Arcellx, Inc. Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. For more information on Arcellx, please visit Follow Arcellx on X @arcellx and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including, but not limited to, statements regarding the safety and efficacy of anito-cel, the promising clinical profile of anito-cel, the expectation of anito-cel to be a differentiated CAR-T treatment option for RRMM, the potential of anito-cel as an outpatient therapy, and the planned commercial development of anito-cel both inside and outside the United States. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including those set forth in Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission (SEC) on May 8, 2025, and the other documents that Arcellx may file from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Hindustan Times
23-04-2025
- Health
- Hindustan Times
Stress to kidney disorder: Doctor breaks down 4 tremors that are not Parkinson's and how to spot them
Not all tremors indicate Parkinson's as various other disorders may cause shaking hence, understanding the differences helps in early diagnosis and proper management. Tremors or involuntary shaking movements are alarming, leading many to fear the worst which is Parkinson's disease however, it is essential to understand that not all tremors are a sign of Parkinsonism. In an interview with HT Lifestyle, Dr Shirish M Hastak, Regional Director of Neurology - Stroke and Neurocritical Care at Gleneagles Hospitals in Mumbai's Parel, explained, 'While Parkinson 's-related tremors are well-known, various other conditions can also cause shaking, many of which are not serious or progressive. Seeking early medical consultation can help in proper diagnosis and treatment.' Dr Shirish M Hastak said, 'Did you know? Tremors are involuntary, rhythmic muscle movements that can impact the parts of the body, mainly the hands, arms, legs, head, or voice. They may occur at rest, during movement, or while maintaining a posture. Tremors can be classified into different types, with Parkinson's tremors being just one category among many. Not all tremors mean Parkinson's disease so please check with your Physician or neurologist.' Parkinson's disease affects movement, causing symptoms such as tremors, stiffness, and slow movements. However, according to Dr Shirish M Hastak, various other conditions can lead to tremors - • Essential Tremor (ET): It is often mistaken for Parkinsonism. It usually affects the hands, head, or voice and worsens with movement, unlike Parkinson's tremor, which occurs more prominently at rest. • Physiological Tremor: Everyone experiences this mild, barely noticeable tremor during exams which can be induced due to stress, fatigue, caffeine, or anxiety. • Dystonic Tremor: Commonly seen in people with dystonia, a condition that causes involuntary muscle contractions, leading to abnormal movements. • Conditions like thyroid disorders, liver or kidney disease and low blood sugar levels can also lead to shaking and tremors. Dr Shirish M Hastak answered, 'Parkinson's tremors improve with movement, whereas essential tremors worsen with movement. Parkinsonian tremors usually start on one side of the body and progress gradually. Other symptoms accompany Parkinson's tremors, such as muscle stiffness, slowness of movement and balance problems.' Dr Shirish M Hastak shared, 'Neurological examination, MRI or CT scans to check for structural brain issues, Blood tests to examine thyroid, kidney and liver functions. Even Dopamine imaging scans (DaTscan) for detecting Parkinson's disease can be advised to the patient if there is uncertainty about the clinical diagnosis.' Treatment depends on the underlying cause. Dr Shirish M Hastak, said, 'For essential tremors, medications like beta-blockers or anticonvulsants can help. Lifestyle changes, stress management, and physical therapy can also be beneficial. In severe cases of essential tremors deep brain stimulation (DBS) may be considered. If tremors result from medication or metabolic disorders, addressing the root cause can often resolve the issue. With the appropriate approach, tremors can often be managed, allowing individuals to live without unnecessary fear or stress.' Talking about how lesioning surgery is also beneficial for some selected patients, Dr Shirish M Hastak said, 'This procedure stands out due to its immediate efficacy, affordability, and longevity. In patients who cannot, use a spoon or a glass due to severe tremors of the hand or the leg, this surgery can improve the quality of life. Lesioning surgery involves creating a small, controlled lesion in a highly targeted brain area.' He concluded, 'For patients who have struggled chronic symptoms of essential tremors for many years, the results are almost miraculous. Moreover, the reduced cost and shorter recovery time make it an accessible solution for many individuals who cannot afford deep brain stimulation. It represents a significant advancement in functional neurosurgery.' Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Yahoo
22-04-2025
- Health
- Yahoo
What is Agent Orange and how is it still impacting Vietnam veterans decades later?
MOUNTAIN HOME, Tenn. (WJHL)- More than 58,000 American soldiers died in the Vietnam War, but the number of those dying from its impacts continues to rise because of Agent Orange. 'It was a very strong herbicide, most famously used in Vietnam. And what it was used for was to clear a very dense tropical vegetation that otherwise would have provided cover for the enemy,' said Dr. Jared Jeffries, the Chief of Occupational and Environmental Medicine at the James H. Quillen Veterans Affairs Medical Center. 19 million gallons of the chemical concoction were sprayed by airplanes, helicopters, trucks and even the soldiers themselves. 'Basically just anybody who had a heavy dose of it, it's going to accumulate more in their body and especially multiple situations where they're exposed,' Jeffries said. 'It can be aerosolized. So if it's been sprayed and dropped, it's droplet aerosolized in the air, you breathe it in. If it contaminates water that you drink or food, you can also get it through skin exposure or a small amount will actually absorb directly through the skin.' Dr. Jared Jeffries and his team at the VA screen veterans for toxic exposures. 'What that is, is a class of chemicals called dioxins, which are very toxic to animals and humans, can cause a bunch of different conditions, have effects on multiple organ systems throughout the body, as well as various types of cancers,' he said. Within the first year of returning home, some Vietnam veterans started having issues with their skin. 'A particular type of acne [is] called chloracne. There's another skin condition called porphyria cutanea tarda, causes damage to the liver. And then also when the skin is exposed to sunlight, it can cause blistering pain.' Then, doctors started noticing exposure to Agent Orange was creating other issues that weren't just on the surface. 'Pretty soon after, like within a year after, people can develop neuropathies in their peripheral nervous systems, their arms and legs. Much later on, we see all types of conditions or neurological conditions, including Parkinsonism, as a big umbrella, and then actual Parkinson's disease, cardiovascular problems,' Jeffries said. 'So ischemic heart disease being a big one. So, blocking out blood to the heart, the coronary arteries. So causing heart attacks and heart failure, hypertension, diabetes, type 2 diabetes, and hypothyroidism. There's a whole host of cancers.' The dioxin TCDD is a byproduct of Agent Orange, and there's no treatment to get rid of it in the body. 'TCDD tends to accumulate in fat. And so the higher the amount that they were exposed to, it can accumulate in fat and then would kind of be released over time,' Jeffries said. Most veterans whom Jeffries and his team screen have multiple conditions presumed to be from Agent Orange. 'We can talk to their primary care [doctor]. We can make recommendations about how to get a better diagnosis,' said Jeffries. 'Perhaps it's labs or imaging or something needs to be done, maybe in a specialist referral, so we can recommend that kind of stuff.' The impacts of Agent Orange can also go beyond the veteran who served, with the possibility of Spina Bifida and other birth defects passed to their immediate children. 'That's a condition where the bones in the spine don't form around the spinal cord correctly, and also the skin,' Jeffries said. 'So either the sac around the spinal cord or the actual spinal cord itself is out and exposed to air. And that has to be repaired and comes along with disability.' Jeffries says that's why it's important to go in and be screened so more research can be done, not only for those who served but for future generations. 'The more research that we have through registries, it allows us to identify more presumptive conditions so that getting through the claims process is not so difficult, that it can be a very expedited process,' said Jeffries. Join News Channel 11 at 5 p.m. on Thursday for the next installment of The Vietnam War: 50 Years Later as we speak to former Congressman Phil Roe about the Blue Water Navy Act. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Los Angeles Times
14-02-2025
- Entertainment
- Los Angeles Times
Brian Setzer of Stray Cats fame reveals autoimmune disease's toll: ‘I cannot play guitar'
For rockabilly musician Brian Setzer, his hands 'cramping up' while on tour with Stray Cats last year was an early sign of a larger health issue. The 65-year-old rocker got candid about his health Thursday, writing on social media that he discovered after returning from tour 'that I have an auto-immune disease.' Setzer, the pompadoured vocalist who rocks with drummer Slim Jim Phantom and bassist Lee Rocker for Stray Cats and also runs his own big-band orchestra, said Thursday, 'I cannot play guitar.' 'There is no pain,' he reassured fans, 'but it feels like I am wearing a pair of gloves when I try to play.' Setzer did not share additional details about his condition but said that for a while it was so bad he couldn't hold a pen or tie his shoes. Since then, he said, he has 'seen some progress' and can now perform those daily tasks. The three-time Grammy winner told followers he has been receiving care at 'the best hospital in the world down the block from me.' 'It's called the Mayo Clinic,' he said. 'I know I will beat this, it will just take some time.' Setzer, prior to sharing his health update, had been promoting both Stray Cats' and his own solo work, including a remastering of his 2000 album 'Vavoom!' Stray Cats kicked off their 2024 summer tour in July and concluded the circuit in mid-August. Months after hitting the road with the Cats, Setzer announced in October that he would hit the road on his own for a solo road trip. 'Going to head up north on the back roads traveling through Field and Farm and enjoying God's beautiful country,' he wrote on Instagram. 'When it gets too cold, I'll turn around. Hopefully the songbird will visit me, and I'll have some new tunes for us soon, God bless you!' Setzer is the latest musician to reveal how their health has affected their ability to make music. In January, Eagles guitarist Steuart Smith, 72, announced he would take a break from performing with the 'Hotel California' group due to a diagnosis of Parkinsonism. Black Sabbath frontman Ozzy Osbourne, 76, also revealed in January that he 'can't walk' amid his battle with Parkinson's disease, which he publicly disclosed in 2020. His wife, Sharon Osbourne, confirmed the Prince of Darkness' condition, telling the Sun in a recent interview that the disease 'affects different parts of the body and it's affected his legs.' Still, she said, her husband's 'voice is as good as it's ever been' and he is 'very emotional' about his impending final bow with Black Sabbath later this year.
